News | November 21, 2025
Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Subscribe To Our Newsletter & Stay Updated
